Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


2-Drug Combo More Effective in Treating Sarcomas, Moffitt Cancer Center Study Shows

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida have found that when given together, a two-drug combination acts synergistically in test animals modeled with sarcoma tumors.
They report that the drug combination of MK-1775 and gemcitabine resulted in a 70 percent decrease in the tumor volume when compared to receiving one drug or the other.

Their study was published in the March 8 online edition of PLOS ONE.

“Sarcomas are rare tumors affecting both children and adults, but sarcomas account for a greater number of pediatric cancers than adult,” said study lead author Soner Altiok, M.D., Ph.D., associate member of the Chemical Biology and Molecular Medicine Program. “Sarcoma response rates to standard chemotherapies have been low, drug toxicity has been high, and improvement in overall survival, especially in metastatic disease, has been negligible. New drugs are needed.”

Sarcomas are cancers that result from transformed cells in one of a number of tissues, including bone, cartilage, fat, muscle and vascular tissues. Sarcomas are different from carcinomas, such as breast, colon and lung cancers.

Researchers from Moffitt’s Chemical Biology and Molecular Medicine and Sarcoma programs had previously collaborated in testing MK-1775’s ability to inhibit Wee1, a protein known to regulate cell size and initiate cell division, an important step in the development of sarcoma. Wee1 plays a role in determining the time at which cell division begins. The researchers found that inhibition of Wee1 by MK-1775 induced cell death in sarcoma tumors.

“Inhibition of the pathways critical to tumor cell survival by molecularly targeted therapy represents an opportunity to reverse the biological basis of tumor formation,” Altiok explained.
To further prove that inhibition of Wee1 by MK-1775 leads to cell death in sarcomas cells, the researchers performed additional studies, including studies on sarcomas-related mutations, such as the p53 gene. They also showed that MK-1775 was an active inhibitor of Wee1 regardless of the p53 mutation status of the tumors in the cell lines tested.

“The toxic effect of Wee1 inhibition on sarcoma cells appeared to be independent of p53 mutation status following our testing sarcoma cell lines with different p53 mutations,” Altiok said. “All of them were highly sensitive to MK-1775, suggesting that Wee1 inhibition may represent a novel approach in the treatment of sarcomas. But p53 status was not predictive of response to MK-1775 as a single agent.”

Because of the success of that previous research, in the new study the Moffitt team investigated the benefits of MK-1775 alone compared to MK-1775 in combination with gemcitabine, a standard chemotherapy drug. They tested the combination in a number of sarcoma cell lines derived from patient tissues and then in animals modeled with osteosarcoma (bone sarcoma).
“The combination of MK-1775 and gemcitabine demonstrated a synergistic effect in sarcoma cells,” explained Altiok. “MK-1775 alone caused tumor cell damage, but when used in combination with gemcitabine, there was increased cell death.”

When the research team tested the combination in laboratory animals, they found that gemcitabine alone inhibited 40 percent of tumor growth. MK-1775 alone inhibited 50 percent of tumor growth. However, MK-1775 and gemcitabine together inhibited 70 percent of tumor cell growth.
“Our data demonstrated that MK-1775 alone and in combination with gemcitabine induces significant cell death in high-grade osteosarcoma cells,” concluded the authors. “This finding lays an important foundation for future clinical trials with MK-1775, which is a well-tolerated, readily available targeted drug.”

About Moffitt Cancer Center
Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, its contributions to clinical trials, prevention and cancer control. Since 1999, Moffitt has been listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer. With more than 4,200 employees, Moffitt has an economic impact on the state of nearly $2 billion. For more information, visit, and follow the Moffitt momentum on Facebook, twitter and YouTube.

Media release by Florida Science Communications

Kim Polacek | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Inflammation Triggers Unsustainable Immune Response to Chronic Viral Infection
24.10.2016 | Universität Basel

nachricht Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Oasis of life in the ice-covered central Arctic

24.10.2016 | Earth Sciences

‘Farming’ bacteria to boost growth in the oceans

24.10.2016 | Life Sciences

Light-driven atomic rotations excite magnetic waves

24.10.2016 | Physics and Astronomy

More VideoLinks >>>